Lisata Therapeutics, Inc. (LSTA)
Lisata Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Basking Ridge, NJ, US. The stock last traded at $1.15, down 5.37% on the session, giving a market capitalisation of $10.4M. On trailing twelve-month figures it carries a trailing P/E of -0.70, a net margin of -14621.0%. Its beta of 0.80 implies it has historically moved less than the broad market.
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Lisata Therapeutics, Inc. is most often compared with the following Healthcare names: